Table 3.
Atrial fibrillation/Atrial tachycardia (AT) recurrence analysis.
| Overall Follow-up | AF/AT-Free | AF/AT Recurrence | P -value* | |
|---|---|---|---|---|
| N | 79 | 43 (54.4) | 36 (45.6) | |
| Gender | ||||
| Men | 58 | 33 (56.9) | 25 (43.1) | 0.634 |
| Women | 21 | 10 (47.6) | 11 (52.3) | |
| Electroanatomical mapping | ||||
| Num. EA points | 7,637.2 ± 3265.0 | 7,405.3 ± 3,047.5 | 7,914.1 ± 3,531.0 | 0.500 |
| Num. CartoFinder sites | 36.4 ± 15.0 | 32.1 ± 10.1 | 41.6 ± 18.1 | 0.007 |
| LA volume (cm3) | 148.2 ± 39.5 | 134.0 ± 33.1 | 165.1 ± 40.4 | <0.001 |
| LA area (cm2) | 164.1 ± 32.5 | 155.8 ± 24.1 | 174.0 ± 38.5 | 0.017 |
| Voltage mapping | ||||
| Mean bipolar voltage (mV) | 0.6 ± 0.3 | 0.6 ± 0.3 | 0.5 ± 0.2 | 0.114 |
| LA area <0.5 mV (%) | 67.2 ± 20.1 | 63.3 ± 20.1 | 71.9 ± 19.1 | 0.047 |
| LA area <0.35 mV (%) | 53.1 ± 21.2 | 48.7 ± 20.1 | 58.3 ± 21.2 | 0.046 |
| LA area <0.1 mV (%) | 20.6 ± 8.5 | 19.2 ± 7.0 | 22.22 ± 9.8 | 0.130 |
| EGM signal analysis | ||||
| EGMs cycle length (ms) | 174.4 ± 80.6 | 176.2 ± 84.2 | 175.6 ± 82.0 | 0.851 |
| EGM electrical burden | 0.3 ± 0.3 | 0.3 ± 0.2 | 0.2 ± 0.2 | <0.001 |
| Mechanistic mapping: rotational activity drivers | ||||
| Num. patients with RAc | 50 (63) | 23 (53) | 27 (75) | 0.048 |
| RAc sites per patient with RAc | 3.7 ± 3.0 | 2.8 ± 1.8 | 4.5 ± 3.6 | 0.040 |
| RAc events per patient with RAc | 71.2 ± 110.1 | 57.9 ± 77.8 | 82.5 ± 130.5 | 0.424 |
| RAc events per acquisition per patient with RAc | 2.0 ± 3.0 | 1.9 ± 2.8 | 2.1 ± 3.1 | 0.799 |
| RAc event duration (ms) | 588.9 ± 459.7 | 591.2 ± 458.9 | 587.8 ± 460.1 | 0.887 |
| Total RAc event durations per RAc acquisition (ms) | 4,351.4 ± 3529.5 | 4,212.0 ± 3,363.6 | 4,425.2 ± 3,612.0 | 0.692 |
| Dominant cycle length for RAc acquisitions | 164.8 ± 24.4 | 167.0 ± 28.5 | 163.6 ± 21.8 | 0.397 |
| Mechanistic mapping: focal activity drivers | ||||
| Num. patients with FA | 79 | 43 (54.4) | 36 (45.6) | |
| FA sites per patient with FA | 13.4 ± 9.2 | 12.8 ± 8.8 | 14.2 ± 9.6 | 0.518 |
| FA events per patient with FA | 758.3 ± 901.4 | 640.8 ± 600.8 | 898.6 ± 1,147.1 | 0.236 |
| FA events per acquisition per patient with FA | 19.7 ± 18.1 | 19.4 ± 16.1 | 20.1 ± 20.3 | 0.870 |
| FA event duration per FA acquisitions (ms) | 276.8 ± 230.2 | 272.1 ± 222.2 | 281.1 ± 237.1 | <0.001 |
| Total FA event durations per FA acquisition (ms) | 5,653.7 ± 5816.1 | 5,419.9 ± 5,544.3 | 5,898.5 ± 6,078.0 | 0.185 |
| Dominant cycle length for FA acquisitions | 173.5 ± 28.9 | 174.9 ± 30.3 | 172.1 ± 27.2 | 0.108 |
| RAc presence location | ||||
| No RAc | 29 (36.7) | 20 (69.0) | 9 (31.0) | 0.002 |
| RAc only inside WACPVI | 9 (11.4) | 8 (88.9) | 1 (11.1) | |
| RAc outside WACPVI | 41 (51.9) | 15 (36.6) | 26 (63.4) |
Values in the table are n (%) or mean ± SD. AF, atrial fibrillation; AT, atrial tachycardia; RAc, rotational activity; WACPVI, wide area circumferential pulmonary vein isolation.
*
Categorical data with the chi-square test for categorical data, continuous variables using Welch's two-sample t-test, and proportions based on normal z-test. Bold values indicates statistical significance.